Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Colorectal Neoplasms 1Adenocarcinoma of the Stomach 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × GC1118 × Clear all
NCT03618667 2023-05-12

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Samsung Medical Center

Phase 2 Completed
13 enrolled
CNS

Glioblastoma

NCT04077255 2022-11-30

EGFR-targeted Therapy for Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown
19 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

NCT02352571 2016-07-06

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

GC Biopharma Corp

Phase 1 Unknown
72 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡